CEO Ronan O’Caoimh Increases Shareholding in Trinity Biotech
June 06 2018 - 8:45AM
Trinity Biotech plc (Nasdaq:TRIB), today announced that Ronan
O’Caoimh, CEO of Trinity Biotech, has increased his shareholding in
Trinity Biotech by the acquisition of 430,000 ADRs. As a result of
this transaction, Mr. O’Caoimh’s shareholding in Trinity Biotech
has increased from 909,374 ADRs to 1,339,374 ADRs which represents
6.4% of the company’s share capital excluding the impact of share
options. The increase in shareholding was due to shares purchased
in the open market.
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
|
|
|
|
|
|
|
|
|
Contact: |
|
|
|
Trinity Biotech
plc |
|
|
|
Lytham Partners
LLC |
|
|
|
|
Kevin Tansley |
|
|
|
Joe Diaz, Joe Dorame
& Robert Blum |
|
|
|
|
(353)-1-2769800 |
|
|
|
602-889-9700 |
|
|
|
|
E-mail:
kevin.tansley@trinitybiotech.com |
|
|
|
|
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Sep 2023 to Sep 2024